Literature DB >> 14647462

Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions.

Shirley L Smith1, Suzanne G Watson, Daniel Ratschiller, Mathias Gugger, Daniel C Betticher, Jim Heighway.   

Abstract

Maspin, SCCA1/2 and hurpin were identified by cDNA microarray analyses as dramatically differentially expressed transcripts in primary non-small cell lung cancer (NSCLC). These sequences are located within a 10-gene serpin cluster on 18q21.3. Using comparative RT-PCR, we have investigated the expression of each of these serpins, including their flanking loci, in an independent NSCLC series. Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently over-represented sequence in both squamous cell carcinoma and adenocarcinoma. Using a well-characterized monoclonal antibody, we have shown strong maspin expression in tumour protein extracts, detected multiple isoforms of the 42 kDa protein and shown that maspin is localized specifically to the tumour cells within neoplastic lesions. In contrast, most cells in non-neoplastic lung tissue appear not to express the gene, with the exception of the multipotent basal epithelial cells that line the bronchial airway. These reserve cells generally show strong predominantly nuclear localization of maspin. Strong nuclear expression of maspin within primary tumour cells is correlated with increased survival (P=0.05) and a longer remission duration (P=0.02) in resectable-staged patients. However, within the airways of cancer patients and somewhat in contrast to this observation, such expression was more frequently detected in the superficial cells of preneoplastic over non-neoplastic epithelia (P<0.0001), consistent with a role for the protein in early neoplasia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647462     DOI: 10.1038/sj.onc.1207127

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Authors:  Bernard W Futscher; Megan M O'Meara; Christina J Kim; Margaret A Rennels; Di Lu; Lynn M Gruman; Richard E B Seftor; Mary J C Hendrix; Frederick E Domann
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

2.  Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

Authors:  Shizhen Emily Wang; Archana Narasanna; Corbin W Whitell; Frederick Y Wu; David B Friedman; Carlos L Arteaga
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

3.  Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method.

Authors:  Seung-Wook Kim; Kyounga Cheon; Chang-Hoon Kim; Joo-Heon Yoon; David H Hawke; Ryuji Kobayashi; Ludmila Prudkin; Ignacio I Wistuba; Reuben Lotan; Waun Ki Hong; Ja Seok Koo
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

Review 4.  SERPINB3 and B4: From biochemistry to biology.

Authors:  Yu Sun; Namratha Sheshadri; Wei-Xing Zong
Journal:  Semin Cell Dev Biol       Date:  2016-09-13       Impact factor: 7.727

5.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

6.  Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis.

Authors:  C Maesawa; S Ogasawara; A Yashima-Abo; T Kimura; K Kotani; S Masuda; Y Nagata; T Iwaya; K Suzuki; T Oyake; Y Akiyama; H Kawamura; T Masuda
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

7.  Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer.

Authors:  Matthias Woenckhaus; Lukas Bubendorf; Peter Dalquen; Julia Foerster; Hagen Blaszyk; Martina Mirlacher; Markus Soler; Wolfgang Dietmaier; Guido Sauter; Arndt Hartmann; Peter J Wild
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

8.  ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.

Authors:  Xiaolong Cheng; Zheng Shen; Litian Yin; Shih-Hsin Lu; Yongping Cui
Journal:  J Biol Chem       Date:  2009-08-28       Impact factor: 5.157

9.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Authors:  David L Masica; Rachel Karchin
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

10.  Binding of extracellular maspin to beta1 integrins inhibits vascular smooth muscle cell migration.

Authors:  Rosemary Bass; Laura Wagstaff; Lorna Ravenhill; Vincent Ellis
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.